Hormone health, handled by a physician, online.
VevaMD is physician-led care for:
• TRT: at-home lab kit, then a live video visit with a board-certified, US-licensed physician
• Menopause HRT: estradiol, progesterone or a non-hormonal option, prescribed only if your physician decides it fits
• ED and intimacy support
• Physician-guided GLP-1 weight loss
Licensed physicians serve patients in all 50 states. HSA and FSA eligible where allowed.
TRT: vevamd.com/trt
HRT: vevamd.com/hrt
Weight loss: vevamd.com/weight-loss
Questions? Reply here or visit vevamd.com
Lean mass and visceral fat, two data sets. 24 trials (1,063 adults): higher-protein deficits kept 0.43 kg more lean mass. 117 studies (4,815 people): exercise cut visceral fat 6.1% with no scale change.
Physician-led weight care: vevamd.com/weight-loss
Testosterone and mood (JAMA Psychiatry 2019): 27 randomized trials, 1,890 men. Treatment linked to fewer depressive symptoms than placebo (Hedges g 0.21; response odds 2.30).
Physician-led TRT online: vevamd.com/trt
SURMOUNT-1 (NEJM 2022): 2,539 adults with obesity, no diabetes. At 72 weeks, tirzepatide mean weight change: −15.0% / −19.5% / −20.9% (5/10/15 mg) vs −3.1% placebo.
GLP-1 care, physician-led (brand, or compounded, not FDA-approved): vevamd.com/weight-loss
ELITE (NEJM 2016): 643 postmenopausal women, oral estradiol 1 mg/day vs placebo, median 5 years. Within 6 years of menopause, carotid IMT rose 0.0044 mm/yr on estradiol vs 0.0078 on placebo. At 10+ years, rates matched.
Menopause HRT online: vevamd.com/hrt
SELECT (NEJM 2023): 17,604 adults 45+ with heart disease, BMI 27+, no diabetes. Over ~40 months, heart attack, stroke or CV death: 6.5% on weekly semaglutide 2.4 mg vs 8.0% on placebo.
GLP-1 care, physician-led (brand, or compounded, not FDA-approved): vevamd.com/weight-loss
TRAVERSE (NEJM 2023) randomized 5,246 men aged 45-80 with low T (two fasting levels under 300 ng/dL) and heart disease or high heart risk. Over ~33 months, major heart events: 7.0% on testosterone gel vs 7.3% on placebo.
Physician-led TRT online: vevamd.com/trt
Perimenopause counts. VevaMD's online menopause hormone therapy is for women 35 to 80 in all 50 states: a physician reviews your private intake, and if prescribed it ships to your door in discreet packaging. No membership fee. vevamd.com/hrt
Type 2 diabetes remission tracked the scale almost step by step in the DiRECT trial (Lancet 2018, 306 UK adults diagnosed within 6 years):
0-5 kg lost: 7%
5-10 kg: 34%
10-15 kg: 57%
15+ kg: 86%
None of the 76 people who gained weight reached remission.
Physician-led weight care, all 50 states: vevamd.com/weight-loss
Low T is diagnosed with symptoms plus a confirmed low morning testosterone on labs. VevaMD's TRT includes labs (at-home kit or your own recent panel) and a live physician visit. 30 states plus DC, HSA and FSA eligible. vevamd.com/trt
Longevity care online in all 50 states. A board-certified physician reviews your intake and decides whether NAD+, glutathione or another option fits. NAD+ is compounded, not FDA-approved. As low as $119/mo all-in; options from $79/mo. vevamd.com/longevity
The Diabetes Prevention Program (NEJM 2002) randomized 3,234 adults with prediabetes. Aiming for 7% weight loss plus 150 min/week of activity cut new type 2 diabetes 58% over ~3 years.
Modest weight loss matters.
Physician-led GLP-1 care, all 50 states: vevamd.com/weight-loss
Most women 40 and over need no labs to start menopause hormone therapy with VevaMD. One price, whatever form your physician chooses: about $67/mo with progesterone, billed $199 every 3 months. Full refund if not prescribed. vevamd.com/hrt
Online TRT, physician-led: an at-home lab kit, then a live video visit with a board-certified, US-licensed physician. As low as $129/mo on the quarterly plan ($387 every 3 months), with medication, labs and visits included. vevamd.com/trt
A high A1C isn't always about sugar.
In 50 non-diabetic adults with iron deficiency anemia, mean A1C was 7.4% vs 5.9% in matched healthy controls. After 3 months of iron it fell to 6.2%.
Lab numbers read best in context.
Source: Coban et al., Acta Haematologica 2004 (50 patients, 50 matched controls). pubmed.ncbi.nlm.nih.gov/1534…
Menopause hormone therapy, physician-led and online in all 50 states. A board-certified physician reviews your intake and decides on estradiol (patch, pill or cream), progesterone or a non-hormonal option. As low as $40/mo, billed $119 every 3 months. vevamd.com/hrt
1,961 adults, 68 weeks, once-weekly semaglutide 2.4 mg or placebo, both with lifestyle support:
Average weight change was -14.9% on semaglutide vs -2.4% on placebo in the NEJM STEP 1 trial. Half the semaglutide group (50.5%) lost 15% or more of their body weight, vs 4.9% on placebo, and physical functioning scores improved more.
Fine print: adults without diabetes; the most common side effects were nausea and diarrhea, typically mild to moderate and fading with time.
Questions about GLP-1 care? Reply, and follow for the research.
doi.org/10.1056/NEJMoa203218…
94 people, 47 couples, one argument staged in a lab:
Couples given oxytocin by nasal spray before a structured conflict discussion showed more positive communication relative to negative behavior, and lower cortisol (a stress hormone) afterward, than couples given placebo. Double-blind, published in Biological Psychiatry.
Fine print: one small lab study, a single dose, measured during one conversation.
Ever notice how closeness changes the tone of a disagreement? Reply, and follow for the research.
doi.org/10.1016/j.biopsych.2…
790 men aged 65+ with low testosterone and symptoms, 1 year of testosterone gel or placebo:
Testosterone significantly increased sexual activity, sexual desire and erectile function in this NEJM report from the NIH-funded Testosterone Trials. Men on testosterone also reported slightly better mood and fewer depressive symptoms, and adverse event rates were similar in both groups.
Fine print: no change in vitality (fatigue) scores, and these were men 65+ with confirmed low levels.
Wondering where your levels sit? Reply, and follow for the research.
doi.org/10.1056/NEJMoa150611…
